olaparib,abiraterone
astrazeneca,merck,janssen
[' ola ', 'crpc']
the question in a real world in patients receiving adt+arta in mhspc scenario is, abi + ola has any role? for those who not receive intensified therapy due to access, the problem will be the same in the mcrpc setting. #esmo2022 
Scientific Committee Member LACOG - GU. Medical Oncologist at Hospital Albert Einstein and CPO. Owner and founder BIO. Following or RT does not mean endorsement